Logo image of MTD

METTLER-TOLEDO INTERNATIONAL (MTD) Stock Fundamental Analysis

USA - NYSE:MTD - US5926881054 - Common Stock

1257.03 USD
-1.02 (-0.08%)
Last: 9/23/2025, 8:04:00 PM
1257.03 USD
0 (0%)
After Hours: 9/23/2025, 8:04:00 PM
Fundamental Rating

5

MTD gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 56 industry peers in the Life Sciences Tools & Services industry. While MTD belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. MTD has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

MTD had positive earnings in the past year.
In the past year MTD had a positive cash flow from operations.
MTD had positive earnings in each of the past 5 years.
In the past 5 years MTD always reported a positive cash flow from operatings.
MTD Yearly Net Income VS EBIT VS OCF VS FCFMTD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

Looking at the Return On Assets, with a value of 24.40%, MTD belongs to the top of the industry, outperforming 98.21% of the companies in the same industry.
MTD's Return On Invested Capital of 39.61% is amongst the best of the industry. MTD outperforms 98.21% of its industry peers.
The Average Return On Invested Capital over the past 3 years for MTD is significantly above the industry average of 14.79%.
Industry RankSector Rank
ROA 24.4%
ROE N/A
ROIC 39.61%
ROA(3y)25.04%
ROA(5y)23.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)41.86%
ROIC(5y)39.3%
MTD Yearly ROA, ROE, ROICMTD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

The Profit Margin of MTD (21.46%) is better than 94.64% of its industry peers.
In the last couple of years the Profit Margin of MTD has grown nicely.
MTD has a Operating Margin of 28.61%. This is amongst the best in the industry. MTD outperforms 100.00% of its industry peers.
MTD's Operating Margin has improved in the last couple of years.
MTD's Gross Margin of 59.94% is fine compared to the rest of the industry. MTD outperforms 78.57% of its industry peers.
In the last couple of years the Gross Margin of MTD has remained more or less at the same level.
Industry RankSector Rank
OM 28.61%
PM (TTM) 21.46%
GM 59.94%
OM growth 3Y2.77%
OM growth 5Y3.56%
PM growth 3Y2.52%
PM growth 5Y3.63%
GM growth 3Y0.93%
GM growth 5Y0.74%
MTD Yearly Profit, Operating, Gross MarginsMTD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so MTD is creating value.
MTD has less shares outstanding than it did 1 year ago.
MTD has less shares outstanding than it did 5 years ago.
MTD has a worse debt/assets ratio than last year.
MTD Yearly Shares OutstandingMTD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
MTD Yearly Total Debt VS Total AssetsMTD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

An Altman-Z score of 10.10 indicates that MTD is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 10.10, MTD belongs to the best of the industry, outperforming 94.64% of the companies in the same industry.
MTD has a debt to FCF ratio of 2.58. This is a good value and a sign of high solvency as MTD would need 2.58 years to pay back of all of its debts.
MTD's Debt to FCF ratio of 2.58 is amongst the best of the industry. MTD outperforms 82.14% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.58
Altman-Z 10.1
ROIC/WACC3.86
WACC10.27%
MTD Yearly LT Debt VS Equity VS FCFMTD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 1.12 indicates that MTD should not have too much problems paying its short term obligations.
With a Current ratio value of 1.12, MTD is not doing good in the industry: 85.71% of the companies in the same industry are doing better.
MTD has a Quick Ratio of 1.12. This is a bad value and indicates that MTD is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of MTD (0.77) is worse than 89.29% of its industry peers.
Industry RankSector Rank
Current Ratio 1.12
Quick Ratio 0.77
MTD Yearly Current Assets VS Current LiabilitesMTD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

4

3. Growth

3.1 Past

MTD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.37%, which is quite good.
MTD shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.53% yearly.
MTD shows a small growth in Revenue. In the last year, the Revenue has grown by 3.10%.
The Revenue has been growing slightly by 5.18% on average over the past years.
EPS 1Y (TTM)8.37%
EPS 3Y6.67%
EPS 5Y12.53%
EPS Q2Q%4.56%
Revenue 1Y (TTM)3.1%
Revenue growth 3Y1.37%
Revenue growth 5Y5.18%
Sales Q2Q%3.85%

3.2 Future

MTD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.06% yearly.
MTD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.03% yearly.
EPS Next Y2.96%
EPS Next 2Y6.58%
EPS Next 3Y8.13%
EPS Next 5Y9.06%
Revenue Next Year3.3%
Revenue Next 2Y3.85%
Revenue Next 3Y4.33%
Revenue Next 5Y4.03%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
MTD Yearly Revenue VS EstimatesMTD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B 5B
MTD Yearly EPS VS EstimatesMTD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 20 40 60

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 30.73, the valuation of MTD can be described as expensive.
Based on the Price/Earnings ratio, MTD is valued a bit cheaper than 64.29% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.41. MTD is around the same levels.
With a Price/Forward Earnings ratio of 26.89, MTD can be considered very expensive at the moment.
MTD's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. MTD is cheaper than 71.43% of the companies in the same industry.
MTD is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.87, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 30.73
Fwd PE 26.89
MTD Price Earnings VS Forward Price EarningsMTD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

69.64% of the companies in the same industry are more expensive than MTD, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, MTD is valued a bit cheaper than the industry average as 66.07% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 30.54
EV/EBITDA 22.81
MTD Per share dataMTD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 -50 100 150

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of MTD may justify a higher PE ratio.
PEG (NY)10.39
PEG (5Y)2.45
EPS Next 2Y6.58%
EPS Next 3Y8.13%

0

5. Dividend

5.1 Amount

MTD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

METTLER-TOLEDO INTERNATIONAL

NYSE:MTD (9/23/2025, 8:04:00 PM)

After market: 1257.03 0 (0%)

1257.03

-1.02 (-0.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)07-31 2025-07-31/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners102.05%
Inst Owner Change-1%
Ins Owners0.42%
Ins Owner Change2.98%
Market Cap25.89B
Analysts71.58
Price Target1330.37 (5.83%)
Short Float %3.31%
Short Ratio4.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.38%
Min EPS beat(2)2.78%
Max EPS beat(2)3.98%
EPS beat(4)4
Avg EPS beat(4)3.18%
Min EPS beat(4)1.02%
Max EPS beat(4)4.94%
EPS beat(8)6
Avg EPS beat(8)3.16%
EPS beat(12)10
Avg EPS beat(12)2.65%
EPS beat(16)14
Avg EPS beat(16)3.36%
Revenue beat(2)1
Avg Revenue beat(2)0.73%
Min Revenue beat(2)-0.18%
Max Revenue beat(2)1.63%
Revenue beat(4)3
Avg Revenue beat(4)1.01%
Min Revenue beat(4)-0.18%
Max Revenue beat(4)2.56%
Revenue beat(8)5
Avg Revenue beat(8)0.5%
Revenue beat(12)8
Avg Revenue beat(12)0.25%
Revenue beat(16)12
Avg Revenue beat(16)0.61%
PT rev (1m)1.41%
PT rev (3m)3.79%
EPS NQ rev (1m)0.49%
EPS NQ rev (3m)1.82%
EPS NY rev (1m)0%
EPS NY rev (3m)1.08%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.26%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.09%
Valuation
Industry RankSector Rank
PE 30.73
Fwd PE 26.89
P/S 6.7
P/FCF 30.54
P/OCF 27.21
P/B N/A
P/tB N/A
EV/EBITDA 22.81
EPS(TTM)40.9
EY3.25%
EPS(NY)46.75
Fwd EY3.72%
FCF(TTM)41.16
FCFY3.27%
OCF(TTM)46.2
OCFY3.68%
SpS187.7
BVpS-12.56
TBVpS-58.08
PEG (NY)10.39
PEG (5Y)2.45
Profitability
Industry RankSector Rank
ROA 24.4%
ROE N/A
ROCE 48.24%
ROIC 39.61%
ROICexc 40.71%
ROICexgc 70.2%
OM 28.61%
PM (TTM) 21.46%
GM 59.94%
FCFM 21.93%
ROA(3y)25.04%
ROA(5y)23.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)41.86%
ROIC(5y)39.3%
ROICexc(3y)43.32%
ROICexc(5y)40.86%
ROICexgc(3y)78.59%
ROICexgc(5y)73.33%
ROCE(3y)50.98%
ROCE(5y)47.86%
ROICexcg growth 3Y5.41%
ROICexcg growth 5Y8.89%
ROICexc growth 3Y5.36%
ROICexc growth 5Y6.84%
OM growth 3Y2.77%
OM growth 5Y3.56%
PM growth 3Y2.52%
PM growth 5Y3.63%
GM growth 3Y0.93%
GM growth 5Y0.74%
F-Score7
Asset Turnover1.14
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.58
Debt/EBITDA 1.73
Cap/Depr 85.07%
Cap/Sales 2.69%
Interest Coverage 250
Cash Conversion 77.47%
Profit Quality 102.18%
Current Ratio 1.12
Quick Ratio 0.77
Altman-Z 10.1
F-Score7
WACC10.27%
ROIC/WACC3.86
Cap/Depr(3y)92.83%
Cap/Depr(5y)94.35%
Cap/Sales(3y)2.85%
Cap/Sales(5y)2.89%
Profit Quality(3y)97.94%
Profit Quality(5y)100.58%
High Growth Momentum
Growth
EPS 1Y (TTM)8.37%
EPS 3Y6.67%
EPS 5Y12.53%
EPS Q2Q%4.56%
EPS Next Y2.96%
EPS Next 2Y6.58%
EPS Next 3Y8.13%
EPS Next 5Y9.06%
Revenue 1Y (TTM)3.1%
Revenue growth 3Y1.37%
Revenue growth 5Y5.18%
Sales Q2Q%3.85%
Revenue Next Year3.3%
Revenue Next 2Y3.85%
Revenue Next 3Y4.33%
Revenue Next 5Y4.03%
EBIT growth 1Y4.27%
EBIT growth 3Y4.18%
EBIT growth 5Y8.92%
EBIT Next Year5.85%
EBIT Next 3Y6.25%
EBIT Next 5Y6.82%
FCF growth 1Y-1.24%
FCF growth 3Y2.57%
FCF growth 5Y11.3%
OCF growth 1Y-1.81%
OCF growth 3Y2.14%
OCF growth 5Y9.92%